Related Experiment Videos
Monoclonal antibody-based therapy for renal cell carcinoma
Egbert Oosterwijk1, Chaitanya R Divgi, Adrienne Brouwers
1Nijmegen Center for Molecular Life Sciences, 190 Experimental Urology, University Medical Center Nijmegen, Geert Grooteplein Zuid 28, 6525 Nijmegen, The Netherlands. e.oosterwijk@uro.umcn.nl
The Urologic Clinics of North America
|September 5, 2003
Abstract:
Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.